Article
Immunology
Timothy Papaluca, Stuart K. Roberts, Simone Strasser, Katherine A. Stuart, Geoffrey Farrell, Gerry MacQuillan, Gregory J. Dore, Amanda J. Wade, Jacob George, Simon Hazeldine, James O'Beirne, Alan Wigg, Leslie Fisher, Bruce McGarity, Rohit Sawhney, Marie Sinclair, James Thomas, Ivan Valiozis, Martin Weltman, Mark Wilson, Aidan Woodward, Golo Ahlenstiel, Mazhar Haque, Miriam Levy, Emily Prewett, William Sievert, Siddharth Sood, Edmund Tse, Zina Valaydon, Scott Bowden, Mark Douglas, Kate New, Jacinta O'Keefe, Margaret Hellard, Joseph Doyle, Mark Stoove, Alexander J. Thompson
Summary: This real-world study confirms the high efficacy of SOF/VEL/VOX for difficult-to-cure NS5A inhibitor experienced patients, particularly those with GT3 and cirrhosis, with an SVR12 rate of 85%. Treatment was generally well tolerated, but serious adverse events may occur in patients with advanced liver disease.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Virology
Steven Flamm, Eric Lawitz, Brian Borg, Michael Charlton, Charles Landis, K. Rajender Reddy, Mitchell Shiffman, Angel Alsina, Charissa Chang, Natarajan Ravendhran, Candido Hernandez, Christophe Hezode, Stacey Scherbakovsky, Renee-Claude Mercier, Didier Samuel
Summary: The study demonstrated that SOF/VEL plus RBV therapy for 12 weeks in patients with HCV-associated decompensated cirrhosis achieved high SVR12 rates and was generally well tolerated.
Article
Gastroenterology & Hepatology
Guiseppe Indolfi, Deirdre Kelly, Gabriella Nebbia, Raffaele Iorio, Anna Mania, Vania Giacomet, Leszek Szenborn, Jiang Shao, Mun Sang Yue, Chia-Hsiang Hsueh, Bandita Parhy, Kathryn Kersey, Alessandra Mangia, Malgorzata Pawlowska, Sanjay Bansal
Summary: Sofosbuvir-velpatasvir-voxilaprevir is a highly effective and well-tolerated pangenotypic regimen for treating chronic HCV infection in adolescents aged 12 to 17 years.
Article
Gastroenterology & Hepatology
Gail V. Matthews, Sanjay Bhagani, Marc Van der Valk, Juergen Rockstroh, Jordan J. Feld, Andri Rauch, Christine Thurnheer, Julie Bruneau, Arthur Kim, Margaret Hellard, David Shaw, Ed Gane, Mark Nelson, Patrick Ingiliz, Tanya L. Applegate, Jason Grebely, Phillipa Marks, Marianne Martinello, Kathy Petoumenos, Gregory J. Dore
Summary: In this randomised study comparing a 6-week course to a 12-week course of sofosbuvir-velpatasvir for recent HCV infection, the shorter course did not meet the criteria for non-inferiority. The study was halted early on advice of the data safety and monitoring board due to lack of efficacy in the 6-week arm.
JOURNAL OF HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Kohei Kotani, Masaru Enomoto, Sawako Uchida-Kobayashi, Akihiro Tamori, Yoshimi Yukawa-Muto, Naoshi Odagiri, Hiroyuki Motoyama, Ritsuzo Kozuka, Etsushi Kawamura, Atsushi Hagihara, Hideki Fujii, Ken Kageyama, Akira Yamamoto, Atsushi Yoshida, Shigeaki Higashiyama, Joji Kawabe, Norifumi Kawada
Summary: In patients with decompensated hepatitis C-related cirrhosis, achieving sustained virologic response (SVR24) with SOF/VEL treatment can improve hepatocyte function and portal hypertension on short-term follow-up.
JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Virology
Toshifumi Tada, Masayuki Kurosaki, Shinichiro Nakamura, Chitomi Hasebe, Yuji Kojima, Koichiro Furuta, Haruhiko Kobashi, Hiroyuki Kimura, Chikara Ogawa, Hitoshi Yagisawa, Yasushi Uchida, Kouji Joko, Takehiro Akahane, Hirotaka Arai, Hiroyuki Marusawa, Ryoichi Narita, Yasushi Ide, Takashi Sato, Atsunori Kusakabe, Keiji Tsuji, Nami Mori, Masahiko Kondo, Akeri Mitsuda, Namiki Izumi
Summary: The study evaluated the efficacy and safety of sofosbuvir and velpatasvir interferon-free DAA therapy in HCV genotype 1- and 2-infected patients with decompensated cirrhosis. The results showed a high SVR rate of 92.3% and no severe adverse events, indicating that the SOF/VEL regimen is effective and safe in this patient population.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Multidisciplinary Sciences
Liyu Chen, Lingyao Du, Shuang Kang, Fanghua Ma, Changmin Li, Min He, Lang Bai, Hong Tang
Summary: In Liangshan, China, people living with HIV have a high prevalence of HCV coinfection. A 24-week regimen of SOF+RBV can achieve good efficacy and is well-tolerated in this population. This treatment has the potential to be generalized in regions with limited resources.
SCIENTIFIC REPORTS
(2021)
Article
Gastroenterology & Hepatology
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, Chun-Jen Liu, Ching-Chu Lo, Ke-Jhang Huang, Jyh-Jou Chen, Kuo-Chih Tseng, Chi-Yang Chang, Cheng-Yuan Peng, Yu-Lueng Shih, Chia-Sheng Huang, Wei-Yu Kao, Sheng-Shun Yang, Ming-Chang Tsai, Jo-Hsuan Wu, Po-Yueh Chen, Pei-Yuan Su, Jow-Jyh Hwang, Yu-Jen Fang, Pei-Lun Lee, Chi-Wei Tseng, Fu-Jen Lee, Hsueh-Chou Lai, Tsai-Yuan Hsieh, Chun-Chao Chang, Chung-Hsin Chang, Yi-Jie Huang, Jia-Horng Kao
Summary: A study conducted in Taiwan showed that the treatment with SOF/VEL plus RBV for 12 weeks is highly effective and well-tolerated for patients with Child-Pugh B/C HCV-related cirrhosis. The SVR12 rates were outstanding, reaching 100%, and patients experienced improvements in liver and kidney function.
CLINICAL AND MOLECULAR HEPATOLOGY
(2021)
Article
Infectious Diseases
Yilihamu Abulitifu, Jiangshan Lian, Munire Adilijiang, Lan Liu, Fengcong Zhao, Wen Qian, Yongping Zhang
Summary: This study investigated the effectiveness and safety of sofosbuvir-velpatasvir (SOF/VEL) with and without ribavirin (RBV) in patients with genotype 3 (GT3) hepatitis C virus (HCV) infection-related cirrhosis from Xinjiang, China. The results showed that SOF/VEL, with or without RBV, was effective and safe for the treatment of GT3 HCV-associated cirrhosis.
INFECTION AND DRUG RESISTANCE
(2022)
Article
Gastroenterology & Hepatology
Yuki Tahata, Hayato Hikita, Satoshi Mochida, Norifumi Kawada, Nobuyuki Enomoto, Akio Ido, Hitoshi Yoshiji, Daiki Miki, Yoichi Hiasa, Yasuhiro Takikawa, Ryotaro Sakamori, Masayuki Kurosaki, Hiroshi Yatsuhashi, Ryosuke Tateishi, Yoshiyuki Ueno, Yoshito Itoh, Taro Yamashita, Tatsuya Kanto, Goki Suda, Yasunari Nakamoto, Naoya Kato, Yasuhiro Asahina, Kentaro Matsuura, Shuji Terai, Kazuhiko Nakao, Masahito Shimizu, Taro Takami, Norio Akuta, Ryoko Yamada, Takahiro Kodama, Tomohide Tatsumi, Tomomi Yamada, Tetsuo Takehara
Summary: This study in Japan evaluated the real-world efficacy and safety of sofosbuvir plus velpatasvir (SOF/VEL) treatment for patients with hepatitis C virus (HCV)-related decompensated cirrhosis. The results showed that the treatment was effective for both compensated and decompensated cirrhosis patients, with similar outcomes to previous studies, but with risks of treatment discontinuation and liver-related deaths. Further evaluation is needed for patients with poor hepatic reserve to determine continuous improvement after viral clearance.
JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Surgery
Marion G. Peters, Shyam Kottilil, Norah Terrault, Dominic Amara, Jennifer Husson, Shirish Huprikar, Sander Florman, Mark S. Sulkowski, Christine M. Durand, Anne F. Luetkemeyer, Rodney Rogers, Joshua Grab, Brandy Haydel, Emily Blumberg, Lorna Dove, Jean Emond, Kim Olthoff, Coleman Smith, Thomas Fishbein, Henry Masur, Peter G. Stock
Summary: The study demonstrates that sofosbuvir-based DAA therapy is safe and highly effective for HCV-HIV coinfected patients with decompensated liver disease and post-liver transplant, with post-transplant survival rates comparable to other indications, removing a significant barrier to liver transplantation in this challenging cohort of recipients.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Immunology
Akinbami Adenugba, Matthias Hornung, Kilian Weigand, Georg Peschel, Henrik Junger, Paul Kupke, Hauke Lang, Jens U. Marquardt, Tim Zimmermann, Edward K. Geissler, Hans J. Schlitt, Jens M. Werner
Summary: Chronic HCV infection is associated with NK cell activation and decreased IFN gamma production, with altered STAT1 and STAT4 phosphorylation. The addition of RBV to DAA therapy for HCV in LTx recipients enhances pSTAT4-dependent IFN gamma-production in NK cells.
Review
Health Care Sciences & Services
JiHyun An, Dong Ah Park, Min Jung Ko, Sang Bong Ahn, Jeong-Ju Yoo, Dae Won Jun, Sun Young Yim
Summary: DAA therapy has shown safety and efficacy in patients with decompensated cirrhosis. The SVR rate was 86%, with low rates of HCC occurrence and mortality. PI-based treatment demonstrated similar clinical outcomes and adverse events compared to non-PI-based DAA treatment in DC patients.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Wan-Long Chuang, Tsung-Hui Hu, Peter Buggisch, Christophe Moreno, Wei-Wen Su, Luigi Biancone, Marianne Camargo, Robert Hyland, Sophia Lu, Brian J. Kirby, Hadas Dvory-Sobol, Anu Osinusi, Anuj Gaggar, Cheng-Yuan Peng, Chen-Hua Liu, Meghan E. Sise, Alessandra Mangia
Summary: The study demonstrated that treatment with ledipasvir/sofosbuvir was safe and effective in patients with end-stage renal disease undergoing dialysis, with 94% achieving sustained virologic response 12 weeks after treatment. Although 13% of patients experienced serious adverse events, none were related to the treatment.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Yoshinari Takaoka, Kouichi Miura, Naoki Morimoto, Tadashi Ikegami, Satoru Kakizaki, Ken Sato, Takashi Ueno, Atsushi Naganuma, Takashi Kosone, Hirotaka Arai, Takeshi Hatanaka, Toshiyuki Tahara, Shigeo Tano, Takaaki Ohtake, Toshimitsu Murohisa, Masashi Namikawa, Takeharu Asano, Toshiro Kamoshida, Katsuhiko Horiuchi, Takeshi Nihei, Atsuko Soeda, Hidekazu Kurata, Takeshi Fujieda, Toshiya Ohtake, Yukimura Fukaya, Makoto Iijima, Shunji Watanabe, Norio Isoda, Hironori Yamamoto
Summary: In this study, 12-week sofosbuvir/velpatasvir treatment was found to be relatively safe and effective for patients with decompensated cirrhosis, significantly improving liver function in the majority of patients. However, the presence of large portosystemic shunt and hyperbilirubinemia were identified as independent factors that interfered with the improvement in the CP score.
HEPATOLOGY RESEARCH
(2021)
